

## CONTENTS

Address of Welcome Professor E. Freerksen . . . . .	1
Chairman's Introduction Dr S. G. Browne . . . . .	3
The Second International Leprosy Colloquium, Borstel; Concept and Aims	
<i>Original Papers Presented at the Colloquium</i>	
1. Chemotherapeutic Trials in Leprosy, their Design and Assessment	
The Role of WHO in Antileprosy Drug Trials, by J. Walter, F. M. Nouisitou and H. Sansarricq . . . . .	9
Chemotherapeutic Trials and their Assessments, by R. J. W. Rees . . . . .	17
The Technique of Evaluating Anti-leprosy Medications at the Forschungsinstitut Borstel, by E. Freerksen . . . . .	25
Pharmacological Aspects of the Chemotherapy of Leprosy, by G. A. Ellard . . . . .	41
Assessment of Treatment Procedures by Means of Bacteriological and Histological Examinations, by M. Rosenfeld . . . . .	53
Problems in the Design of Medium and Long-term Therapeutic Trials, by D. S. Ridley . . . . .	59
Chemotherapeutic Trials in Patients with Non-Lepromatous Leprosy, by J. M. H. Pearson . . . . .	63
2. Current Concerns in the Chemotherapy of Leprosy	
(a) Monotherapy	
Viability of <i>Myco. leprae</i> in the Skin and Bone Marrow of Patients with Lepromatous Leprosy While on Dapsone or Lamprene, by A. B. A. Karat . . . . .	69
Effect of Mono Treatment and Combined Treatment on the Morphology of <i>Myco. leprae</i> in the Skin, by D. L. Leiker . . . . .	73
Treatment of Leprosy with Clofazimine, Rifampicin and Bayrena, by J. Languillon . . . . .	81
A Preliminary Report on a Therapeutic Trial with Acedapsone in Lepromatous Leprosy, by K. Ramanujam, C. G. S. Iyer and G. Ramu . . . . .	85
Low Dose Dapsone Treatment in Lepromatous Leprosy, by A. B. A. Karat . . . . .	89
A Report on a Controlled Clinical Trial with Conventional and One Third Conventional Dose of Dapsone Administered Orally Once a Week in Lepromatous Patients, by K. Ramanujam, C. G. S. Iyer and G. Ramu . . . . .	93
Personal Experience with Clofazimine in the Treatment of Leprosy, by R. D. Azulay, N. C. da Silva, A. Zeo, M. de Jesus and C. B. Franca . . . . .	99

Long-term Follow-up of Clofazimine (Lamprene) in the Management of Reactive Phases of Leprosy, by A. B. A. Karat . . . . .	105
The Effect of Long-term Steroid Therapy on Patients Treated with Clofazimine (Lamprene), by L. M. Hogerzeil and N. Prabhudas . . . . .	111
Open Trial with Clofazimine in the Management of Recurrent Lepra Reaction and of Sulphone Sensitive Cases: A Preliminary Report, by K. Ramanujam, C. G. S. Iyer and G. Ramu . . . . .	117
Rifampicin: The Investigation of a Bactericidal Antileprosy Drug, by R. J. W. Rees . . . . .	121
The Use of Rifampicin in the Treatment of Leprosy, by E. J. Saelens . . . . .	125
A Controlled Clinical Trial of Continuous and Intermittent Rifampicin Therapy During an Initial Three Months Period in Lepromatous leprosy: Final Analysis, by S. R. Pattyn, M. T. Rollier, R. Rollier, E. J. Saelens and P. Dockx . . . . .	129
Antibiotics in Leprosy, with Special Reference to Rifampicin, by D. V. A. Opromolla and C. J. S. Tonello . . . . .	141
The Effect of a Single Dose of Rifampicin on the Infectivity of the Nasal Discharge in Leprosy (Preliminary Communication), by L. M. Hogerzeil and R. J. W. Rees . . . . .	147
Results of Leprosy Control Project, Malawi, by B. D. Molesworth . . . . .	149

## 2. Current Concerns in the Chemotherapy of Leprosy (b) Combined Therapy

Combined Therapy in Leprosy, by J. C. Gatti . . . . .	155
Preliminary Experience with Combined Therapy using Rifampicin and Isoprodian (L73A), by E. Freerksen . . . . .	161
Treatment of Leprosy with Rifampicin and Isoprodian (L73A), by J. Terencio de las Aguas . . . . .	165
Clinical and Bacteriological Effects of Rifampicin in Combination with L73A in Leprosy: Observation for Six Months, by S. Innami, O. R. Leguizamón and A. E. Alvarenga . . . . .	169
Treatment of Leprosy with Rifampicin and Isoprodian in 38 Patients at St. Thomas Hospital, Chetput, South India, by M. Aschhoff . . . . .	173
Rifampicin and Isoprodian in Combination in the Treatment of Leprosy, by G. Depasquale . . . . .	179
Preliminary Experience with Rifampicin and Isoprodian (L73A)—Combination in Lepromatous Leprosy, by M. Hamzah and A. Kosasih . . . . .	181
Preliminary Experience with Rifampicin and Isoprodian in Combination in Leprosy Treatment, by H. N. Krenzien . . . . .	189
Report of Combined Therapy in Leprosy with Rifampicin and Isoprodian—Conducted at the Bisidimo-Center, Ethiopia, by R. Rohde . . . . .	199
Preliminary Report of a Drug Trial conducted at Leprosy Relief Rural Centre, Chettipatty, South India, by E. Vomstein . . . . .	207

The Leprosy Eradication Programme of Malta, by G. Depasquale . . . . .	215
Discussion	
Part I Criteria for the Assessment of Drug Activity . . . . .	221
I.1 Clinical Criteria . . . . .	221
I.2 Bacteriological Assessment of Drug Activity . . . . .	226
I.3 Animal Models . . . . .	231
Part II Current Concerns in Therapeutic Research . . . . .	233
II.1 Persistent <i>Myco. leprae</i> . . . . .	233
II.2 Drug Resistance . . . . .	235
II.3 Combined Therapy . . . . .	239
II.4 Transfer Factor . . . . .	245
Part III Clinical Trials . . . . .	247
III.1 Choice of Patients . . . . .	247
III.2 Duration of Trials . . . . .	249
III.3 Duration of Therapy . . . . .	250
III.4 Criteria for Non-infectivity . . . . .	254
III.5 Intermittent <i>versus</i> Continuous Therapy: Toxicity and Side Effects	255
Part IV Practical Problems of Chemotherapy in Leprosy . . . . .	258
IV.1 Clinical and Laboratory Control in Field Projects . . . . .	258
IV.2 Prevention . . . . .	260
IV.3 Combined Leprosy and Tuberculosis Control . . . . .	261
IV.4 Practicability . . . . .	263
List of Participants . . . . .	265
Index . . . . .	269